Mycophenolatmofetil Tillomed (Mycophenolate Mofetil)

Mycophenolate Mofetil acts on the immune system to reduce abnormal lymphocyte activity in several disease settings.

• Organ transplant rejection: helps prevent graft loss by inhibiting T‑cell proliferation.
• Lupus nephritis: reduces renal inflammation and proteinuria in systemic lupus erythematosus.
• Other autoimmune diseases (e.g., systemic lupus erythematosus): suppresses overall immune activity to control disease flares.

• Mycophenolate Mofetil is converted intracellularly to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). This blockade reduces guanosine nucleotide synthesis, a pathway essential for the proliferation of B and T lymphocytes, thereby dampening the adaptive immune response.

Adverse reactions may occur with Mycophenolate Mofetil therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: frequent loose stools.
• Headache: transient cranial discomfort.
• Infections (upper respiratory): increased susceptibility to common colds.

Serious or Rare Side Effects

• Bone marrow suppression: leukopenia or anemia requiring monitoring.
• Severe infections: opportunistic pathogens such as CMV or fungal infections.
• Liver toxicity: elevated transaminases or hepatitis.

Before initiating therapy, clinicians should consider several safety measures.

• Monitor blood counts: perform regular CBC to detect leukopenia or anemia.
• Assess liver function: periodic LFTs to identify hepatotoxicity.
• Avoid live vaccines: heightened risk of vaccine‑derived infection.
• Pregnancy considerations: discuss potential fetal risks with the prescriber.
• Store at room temperature: keep in the original container, protect from moisture.

Mycophenolate Mofetil can interact with several drug classes.

Major Interactions (Avoid)

• Antimetabolites (e.g